Gastroenterology
Volume 137, Issue 4 , Pages 1204-1206 , October 2009

Is Keeping the Colon the Ultimate Marker of Success in Ulcerative Colitis?

  • Geoffrey C. Nguyen, MD, PhD

      Affiliations

    • Mount Sinai Hospital IBD Centre, University of Toronto, Toronto, Ontario, Canada and The Johns Hopkins Division of Gastroenterology and Hepatology, Baltimore, Maryland
    • ,
  • Charlene M. Prather, MD, MPH

      Affiliations

    • Saint Louis University Division of Gastroenterology and Hepatology, St. Louis, Missouri
    • Corresponding Author InformationReprint requests Address requests for reprints to: Charlene M. Prather, MD, MPH, 3635 Vista Avenue, FDT-9, St. Louis, Missouri 63110

References 

  1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476
  2. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805–1811
  3. Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:507–515
  4. Jess T, Loftus EV, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted county, Minnesota. Gastroenterology. 2006;130:1039–1046
  5. Winther KV, Jess T, Langholz E, et al. Long-term risk of cancer in ulcerative colitis: a population–based cohort study from Copenhagen county. Clin Gastroenterol Hepatol. 2004;2:1088–1095
  6. Muir AJ, Edwards LJ, Sanders LL, et al. A prospective evaluation of health-related quality of life after ileal pouch anal anastomosis for ulcerative colitis. Am J Gastroenterol. 2001;96:1480–1485
  7. McLeod RS, Churchill DN, Lock AM, et al. Quality of life of patients with ulcerative colitis preoperatively and postoperatively. Gastroenterology. 1991;101:1307–1313
  8. Meagher AP, Farouk R, Dozois RR, et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998;85:800–803
  9. Maclean AR, Cohen Z, Macrae HM, et al. Risk of small bowel obstruction after the ileal pouch-anal anastomosis. Ann Surg. 2002;235:200–206
  10. Waljee A, Waljee J, Morris AM, et al. Three-fold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut. 2006;55:1575–1580
  11. Aratari A, Papi C, Clemente V, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis. 2008;40:821–826
  12. Actis GC, Fadda M, David E, et al. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol. 2007;7:13;13
  13. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250–1260
  14. Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006;101:1012–1023
  15. Nguyen GC, LaVeist TA, Gearhart S, et al. Racial and geographic variations in colectomy rates among hospitalized ulcerative colitis patients. Clin Gastroenterol Hepatol. 2006;4:1507–1513
  16. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:935–939
  17. Stukel TA, Fisher ESWennberg, et al. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA. 2007;297:278–285

 Conflicts of interest The authors disclose the following: Dr Nguyen has served on advisory boards for Schering-Plough, Canada, and Abbott Pharmaceuticals before the writing of this editorial. Dr Nguyen was not involved with the design or conduct of the ACT-1 or ACT-2 trials nor does he have any collaborative relationship with any of the investigators. There was no communication or input from any of the investigators or from any pharmaceutical company with regards to the contents of this editorial.

 Dr Prather has served as a consultant for Proctor and Gamble. Dr Prather was not involved with the design or conduct of the ACT-1 or ACT-2 trials nor does she have any current or prior collaborative relationship with any of the investigators or the sponsor of the study. There was no communication or input from any of the investigators or from any pharmaceutical company with regards to the contents of this editorial.

PII: S0016-5085(09)01489-9

doi: 10.1053/j.gastro.2009.08.024

Gastroenterology
Volume 137, Issue 4 , Pages 1204-1206 , October 2009

Article Tools